Abstract:Primary liver cancer, which is scientifically referred to as hepatocellular carcinoma (HCC), is a significant concern in the field of global health. It has been demonstrated that conventional chemotherapy, chemo-hormonal therapy, and conformal radiotherapy are ineffective against HCC. New therapeutic approaches are thus urgently required. Identifying single or multiple mutations in genes associated with invasion, metastasis, apoptosis, and growth regulation has resulted in a more comprehensive comprehension of the molecular genetic underpinnings of malignant transformation, tumor advancement, and host interaction. This enhanced comprehension has notably propelled the development of novel therapeutic agents. Therefore, gene therapy (GT) holds great promise for addressing the urgent need for innovative treatments in HCC. However, the complexity of HCC demands precise and effective therapeutic approaches. The adeno-associated virus (AAV) distinctive life cycle and ability to persistently infect dividing and nondividing cells have rendered it an alluring vector. Another appealing characteristic of the wild-type virus is its evident absence of pathogenicity. As a result, AAV, a vector that lacks an envelope and can be modified to transport DNA to specific cells, has garnered considerable interest in the scientific community, particularly in experimental therapeutic strategies that are still in the clinical stage. AAV vectors emerge as promising tools for HCC therapy due to their non-immunogenic nature, efficient cell entry, and prolonged gene expression. While AAV-mediated GT demonstrates promise across diverse diseases, the current absence of ongoing clinical trials targeting HCC underscores untapped potential in this context. Furthermore, gene transfer through hepatic AAV vectors is frequently facilitated by GT research, which has been propelled by several congenital anomalies affecting the liver. Notwithstanding the enthusiasm associated with this notion, recent discoveries that expose the integration of the AAV vector genome at double-strand breaks give rise to apprehensions regarding their enduring safety and effectiveness. This review explores the potential of AAV vectors as versatile tools for targeted GT in HCC. In summation, we encapsulate the multifaceted exploration of AAV vectors in HCC GT, underlining their transformative potential within the landscape of oncology and human health.

625. AAV Gene Therapy for Liver Metastatic Cancer

Long-Term Expression of Angiostatin Suppresses Metastatic Liver Cancer in Mice

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Selective in Vivo Targeting of Human Liver Tumors by Optimized Aav3 Vectors in A Murine Xenograft Model

Suppression of Lung Tumor Growth and Metastasis in Mice by Adeno-Associated Virus-Mediated Expression of Vasostatin

Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

Adeno-Associated Virus Gene Therapy for Liver Disease

Recombinant Adeno-Associated Virus-Mediated Trail Gene Therapy Suppresses Liver Metastatic Tumors

AAV-mediated gene transfer of DNase I in the liver of mice with colorectal cancer reduces liver metastasis and restores local innate and adaptive immune response

Advancing Liver Gene Therapy: Enhanced Transduction with GalNAc-Bioconjugated rAAV Capsids

Adeno-associated Virus-Mediated Cancer Gene Therapy: Current Status.

Gene-viro-therapy Targeting Liver Cancer by a Dual-Regulated Oncolytic Adenoviral Vector Harboring IL-24 and TRAIL

974. Adeno-Associated Viral (Aav)-Mediated Gene Transfer of Soluble Vascular Endothelial Growth Factor Receptor 3 (svegfr3) Inhibits Development of Lymph Node Metastases

Development of Optimized AAV3 Serotype Vectors: Mechanism of High-Efficiency Transduction of Human Liver Cancer Cells

Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma

Therapeutic Targeting of Liver Cancer with A Recombinant Dna Vaccine Containing the Hemagglutinin-Neuraminidase Gene of Newcastle Disease Virus Via Apoptotic-Dependent Pathways

Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists

Cancer Gene Therapy of Adenovirus-Mediated Anti-4-1bb Scfv in Immunocompetent Mice

The Feasibility and Mechanism of Recombinant Adenovirus Ad - P 14 ARF in Gene Therapy of Liver Cancer